| Dr Matthew T Neal, MD | |
|
2145 Henry Tecklenburg Dr Ste 220, Charleston, SC 29414-5894 | |
| (843) 723-8823 | |
| Not Available |
| Full Name | Dr Matthew T Neal |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 16 Years |
| Location | 2145 Henry Tecklenburg Dr Ste 220, Charleston, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023270386 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 87877 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Roper-st. Francis Home Health | Charleston, SC | Home health agency |
| Bon Secours-st Francis Xavier Hospital | Charleston, SC | Hospital |
| Mount Pleasant Hospital | Mount pleasant, SC | Hospital |
| Roper Hospital | Charleston, SC | Hospital |
| Roper St Francis Hospital-berkely Inc | Moncks corner, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Roper Saint Francis Physicians Network | 5193874824 | 415 |
News Archive
King Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection.
Epizyme today announced a worldwide strategic alliance with GlaxoSmithKline to discover, develop, and market novel small molecule therapeutics targeting histone methyltransferases, an important class of epigenetic enzymes, for the treatment of cancer and other diseases.
By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."
The decision to perform an invasive procedure to open clogged arteries in the heart instead of first trying medication and lifestyle changes may not reduce a patient's risk of death or of a major cardiac event. Unnecessary procedures to treat chronic, stable heart disease contribute to rising health care costs.
A team from the Metastasis Research Laboratory (GIGA-Cancer/Liège University Hospital) has just published, in the prestigious journal BLOOD, their work demonstrating that the DMP1 protein has previously unsuspected anti-angiogenic activities which could be used for the development of new treatments against cancer, but also against diseases in which angiogenesis plays a major role, such as psoriasis, rheumatoid arthritis or diabetic retinopathy.
› Verified 7 days ago
| Entity Name | Roper Saint Francis Physicians Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346752383 PECOS PAC ID: 5193874824 Enrollment ID: O20090528000405 |
News Archive
King Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection.
Epizyme today announced a worldwide strategic alliance with GlaxoSmithKline to discover, develop, and market novel small molecule therapeutics targeting histone methyltransferases, an important class of epigenetic enzymes, for the treatment of cancer and other diseases.
By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."
The decision to perform an invasive procedure to open clogged arteries in the heart instead of first trying medication and lifestyle changes may not reduce a patient's risk of death or of a major cardiac event. Unnecessary procedures to treat chronic, stable heart disease contribute to rising health care costs.
A team from the Metastasis Research Laboratory (GIGA-Cancer/Liège University Hospital) has just published, in the prestigious journal BLOOD, their work demonstrating that the DMP1 protein has previously unsuspected anti-angiogenic activities which could be used for the development of new treatments against cancer, but also against diseases in which angiogenesis plays a major role, such as psoriasis, rheumatoid arthritis or diabetic retinopathy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew T Neal, MD Po Box 751649, Charlotte, NC 28275-1649 Ph: (843) 789-1620 | Dr Matthew T Neal, MD 2145 Henry Tecklenburg Dr Ste 220, Charleston, SC 29414-5894 Ph: (843) 723-8823 |
News Archive
King Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection.
Epizyme today announced a worldwide strategic alliance with GlaxoSmithKline to discover, develop, and market novel small molecule therapeutics targeting histone methyltransferases, an important class of epigenetic enzymes, for the treatment of cancer and other diseases.
By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."
The decision to perform an invasive procedure to open clogged arteries in the heart instead of first trying medication and lifestyle changes may not reduce a patient's risk of death or of a major cardiac event. Unnecessary procedures to treat chronic, stable heart disease contribute to rising health care costs.
A team from the Metastasis Research Laboratory (GIGA-Cancer/Liège University Hospital) has just published, in the prestigious journal BLOOD, their work demonstrating that the DMP1 protein has previously unsuspected anti-angiogenic activities which could be used for the development of new treatments against cancer, but also against diseases in which angiogenesis plays a major role, such as psoriasis, rheumatoid arthritis or diabetic retinopathy.
› Verified 7 days ago
Steven Steuer Glazier, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. John D Steichen, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2145 Henry Tecklenburg Dr Ste 220, Charleston, SC 29414 Phone: 843-723-8823 Fax: 843-606-8059 | |
Ricardo Alfonso Domingo Cabreja, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 169 Ashley Ave Rm 202, Charleston, SC 29425 Phone: 843-792-2424 | |
Clayton Lee Haldeman, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2145 Henry Tecklenburg Dr Ste 220, Charleston, SC 29414 Phone: 843-723-8823 | |
Dr. Sunil J Patel, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Dr. Stephen Robert Lowe, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 169 Ashley Ave, Room 202 Main Hospital Msc 333, Charleston, SC 29425 Phone: 843-792-1414 Fax: 843-792-9295 |